Australian Study Explores Relative Cost Effectiveness of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
31
Australian Study Explores Relative Cost Effectiveness of Different Treatment Programs: Modelling Suggests Potential Long-term Advantage of Referral to Dedicated Weight Management Program

Silver Spring, MD, Aug. 27, 2018 (GLOBE NEWSWIRE) -- New research suggests that cost savings could be realized when patients receive a referral to a commercial weight management program instead of receiving care from their primary care provider alone, according to a study published in the August issue of Obesity . The University of Sydney study is the first to use a modelling approach to predict the potential population cost effectiveness of referral to a dedicated weight management program for weight management. Based on the outcomes of the simulation, the authors estimate that over a 10-year period, implementation of physician referral to a local Weight Watchers program might help avert as many as 60,500 cases of obesity nationwide and reduce obesity-related healthcare costs by as much as $17 million (Australian dollars).

“Primary care professionals are facing an increasing number of patients with obesity needing treatment,” said Dr. Sharyn Lymer, the study’s lead author and research fellow at the Boden Institute of Obesity Nutrition, Exercise and Eating Disorders at the University of Sydney in Australia. Lymer added that the results of the study suggest another potentially more cost effective treatment opportunity. The study’s authors explain that the obesity epidemic continues to persist in Australia. More than 63 percent of Australians aged 18 years and older had overweight or obesity in 2014 and 2015. The excess cost of direct healthcare for Australians aged 18 years and older who have obesity was reported at $3.8 billion (Australian dollars) in 2015—equivalent to 2.5 percent of the total Australian healthcare cost. To determine the potential cost savings with a referred care approach, researchers used microsimulation—a method of modelling real-life events by simulating the actions of individual units that comprise a system. Researchers modelled the Australian population with eligibility for the intervention for those between the ages of 20 to 64 who had a body mass index (BMI) equal to or higher than 27 kg/m 2 . In the simulation, it was assumed that 17.5 percent of eligible participants would opt to receive a referral from their primary care physician to attend a weekly community meeting of the Weight Watchers program and that 61 percent of those would complete the one-year program. For those receiving standard care, the model assumed the same participation rate but with a 54 percent completion rate.  The standard care approach included receiving weight management advice and monitoring from their general practitioner or primary care physician for an average of ten 20-minute consultations over a year.  Simulations of both interventions were used to predict population health outcomes after one, five and 10 years. The model predicted that referral to a commercial program would lead to a one percent decrease in the prevalence of obesity after one year, while use of the standard care approach would generate a half percent decrease.  Both decreases are predicted to continue over the full 10-year period modelled.  The authors also note that the model predicted that the commercial weight management intervention would perform better on every health and economic outcome examined. The authors note that while simulations predicted that both interventions would reduce the number of adults with obesity, neither approach would allow the country to meet the World Health Organization recommendations for population obesity levels in 2025. Lymer and Michelle Cardel, PhD, MS, RD, FTOS, an assistant professor in the Department of Health Outcomes and Biomedical Informatics at the University of Florida College of Medicine, both agree that greater access to care is needed, including population-level, cost-effective interventions to address obesity. “The use of a simulation model to predict cost-savings for the Weight Watchers-based program as an obesity treatment provides interesting and novel data” said Cardel. “While this is exciting news, simulation models are a simplification of the complex reality that can occur when seeking obesity treatment, and thus possesses inherent limitations. Future study is needed to assess if provider referral to Weight Watchers on a large-scale would result in clinically meaningful weight loss over the long-term.” The development of the microsimulation model used in this study was funded by a National Health and Medical Research Council program grant. Weight Watchers International provided no financial or other support for this study, and the authors declared no research funding or other remuneration from Weight Watchers. Lymer, Deborah Schofield and Stephen Colagiuri have received grants for other research from Novo Nordisk. Nicholas Fuller and Ian Caterson have received research grants from Sanofi, Allergan, Eli Lilly and Novo Nordisk. Caterson was a board member for the SCOUT trial, is on the EXSCEL Operations Committee, and has received payment for lectures from iNova Pharmaceuticals, Pfizer Australia and Servier Laboratories (Australia). Michelle Cunich and Crystal Man Ying Lee declared no conflict of interest.

#   #   #

 

This press release can be published in full or in part with attribution to The Obesity Society.

The Obesity Society (TOS) is the leading organization of scientists and health professionals devoted to understanding and reversing the epidemic of obesity and its adverse health, economic and societal effects.  Combining the perspective of physicians and other clinicians, scientists, policymakers and patients, TOS promotes innovative research, education, and evidence-based clinical care to improve the health and well-being of all people with obesity. For more information, visit www.obesity.org and connect with us on Facebook , Twitter and LinkedIn .

Kristin D. Collins The Obesity Society 240-485-1950 kcollins@obesity.org

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 5

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading

Top 5 Most Recently Viewed Articles

U Power Limited Advances Electric Vehicle Solutions in Europe

Updated Category News Views 239

U Power Limited Expands Its European Reach U Power Limited (Nasdaq: UCAR) is making significant strides in the electric vehicle (EV) landscape. The company, known for its innovative battery-swapping technology, has announced an exciting joint venture that enhances their presence in the European market. This strategic move is expected to reshape how electric mobility is...

Continue Reading
UKG Stands Out as a Top Leader in Workforce Management Solutions

Updated Category News Views 163

UKG Secures Top Spot in Workforce Management UKG, a leading provider in HR, payroll, workforce management, and cultural solutions, has recently earned recognition for its exceptional contributions to the workforce management field. The company has been named a Leader in the NelsonHall New World Workforce Management 2024 evaluation, showcasing its strong performance across...

Continue Reading
Prominent Movers in Today's Market: Micron, Accenture Rise

Updated Category News Views 141

As the trading day unfolds, the US stock market is witnessing a shift, with several companies experiencing significant movements in their stock prices. Recent trends show that investors are closely monitoring the market after a minor disruption in gains. Micron's Robust Performance Micron Technology (NASDAQ: MU) has captured the spotlight today, with shares surging by an...

Continue Reading
Celebrate 1.5 Years of Obey Me! Nightbringer with Exciting Events

Updated Category News Views 85

Celebrating 1.5 Years of Obey Me! Nightbringer Obey Me! Nightbringer is reaching a significant milestone, celebrating its 1.5-year anniversary. This beloved mobile game from NTT Solmare has captured the hearts of players around the globe, and to acknowledge this momentous occasion, the developers are rolling out a variety of exciting events. Four Exciting Events for...

Continue Reading
Celebrating Innovation: 2026 sofi™ Awards Winners Unveiled

Updated Category News Views 219

Celebrating Culinary Excellence: The 2026 sofi™ Awards NEW YORK — The Specialty Food Association (SFA) revealed the much-anticipated results of the 2026 sofi™ Awards at the Winter FancyFaire event. This celebrated gathering brought together industry leaders, chefs, makers, and buyers to applaud the finest in specialty food and beverage innovation. A Night of...

Continue Reading